SeromYx is a specialized Contract Research Organization (CRO) founded in July 2019 with the aim of commercializing the groundbreaking Systems Serology platform. Developed by Dr. Galit Alter at the Ragon Institute of Harvard/MIT/MGH, this platform incorporates 12 high-throughput assays and utilizes machine learning computational analysis.

As a fee-for-service CRO, SeromYx operates with no entanglement of client intellectual property. The SeromYx platform focuses on measuring Fc mediated antibody effector functions by recruiting innate immune cells to effectively clear pathogens, infected cells, or tumor cells. By determining the specific functions that drive efficacy, SeromYx helps pharmaceutical and biotechnology companies design future vaccines and immunotherapies that elicit these functions, resulting in better products.

The mission of SeromYx is to provide clients with unprecedented insight into immune function using their proprietary tools so that they can discover and develop more effective vaccines, immunotherapies, drugs, and diagnostics. The company offers a wide range of services and expertise, tailored to the specific needs and goals of each individual project. To learn more about SeromYx and discuss your project, get in touch with them today